Table 2.

 Effect on inflammation after the first infusion with infliximab

Patient	Eye	VA T = 0	VAT = 0+x	AC T = 0	AC T = 0+x	AH T = 0	AH T = 0+x	VC T = 0	VC T = 0+x	F T = 0	F T = 0+x	x (days after infusion)
1	RE	20/30	20/25	3	1	2	1	2	1	1	0	7
	LE	LP+	CF	3	1	2	1	2	1	1	0
2	RE	20/50	20/30	2	1	2	1	1	0	0	0	6
	LE	LP+	LP+	2	1	1	1	2	1	1	0
3	RE	20/60	20/40	2	0	2	1	1	0	1	0	14
	LE	0.6	20/25	1	0	1	1	2	0	0	0
4	RE	CF	CF	2	0	2	1	2	1	1	0	21
	LE	20/30	20/30	2	0	1	1	1	0	0	0
5	RE	20/200	20/100	2	1	2	1	2	1	1	0	9
	LE	Enucleated
6	RE	CF	20/200	2	1	2	1	1	0	1	0	17
	LE	Phthisis bulbi
A	RE	20/150	20/80	3	2	3	2	3	2	1	0	6
	LE	20/200	20/100	2	1	2	2	2	1	1	0
B	RE	20/40	20/20	2	1	2	1	1	1	1	0	21
	LE	CF	20/150	2	1	3	1	1	1	1	0
C	RE	20/50	20/40	1	0	1	1	1	1	1	0	30
	LE	LP+	LP+	0	0	0	0	1	0	1	0
D	RE	20/400	20/200	2	0	2	0	1	0	1	0	55
	LE	20/120	20/120	2	0	1	0	0	0	1	0
E	RE	20/200	20/200	1	1	3	1	1	1	1	0	12
	LE	20/200	20/200	0	1	1	1	1	1	1	0
F	RE	20/40	20/40	3	0	2	1	1	0	0	0	6
	LE	20/60	20/40	2	0	1	0	2	1	1	0
G	RE	20/120	20/60	0	0	0	0	1	1	0	0	70
	LE	CF	20/200	0	0	0	0	1	1	0	0

VA, visual acuity according to Snellen equivalent; AH, aqueous haze; F, fundus (presence of vasculitis: 1; no vaculitis: 0); AC, aqueous cell; T, time; VC, vitreous cell; CRVO, central retinal vein occlusion.

x: number of days after start of the first treatment when re-examination was performed.